Targeted screening for melanoma after a 5-year follow-up: Comparison of melanoma incidence and lesion thickness at diagnosis in screened (versus unscreened) patients - 20/12/21

Doi : 10.1016/j.lpmope.2021.100013 
Cédric Rat a, b, , Laurie Blachier a, Sandrine Hild a, Florence Molinie c, Aurélie Gaultier d, Brigitte Dreno b, e, Jean-Michel Nguyen b, d
a Department of General Practice, Faculty of Medicine, 1 rue G. Veil, 44000 Nantes, France 
b French National Institute of Health and Medical Research, CRCINA, 8 quai Moncousu, 44007 Nantes Cedex 1, France 
c Cancer Registry for the Loire-Atlantique and Vendée Geographic Areas, 50 route de Saint Sébastien, 44200 Nantes, France 
d Department of Epidemiology and Biostatistics, CHU Nantes, Nantes University, 85 rue Saint Jacques, 44093 Nantes Cedex 1, France 
e Department of Dermatology, CHU Nantes, Nantes University, 1 place Alexis Ricordeau, 44093 Nantes Cedex 1, France 

Corresponding author at: Cédric Rat, Department of General Practice, Faculty of Medicine of Nantes, 1 rue Gaston Veil, 44035 Nantes, France.Cédric RatDepartment of General Practice, Faculty of Medicine of Nantes1 rue Gaston VeilNantes44035France

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Key points

Question: Could a targeted melanoma screening strategy using the Self-Assessment of Melanoma risk score be effective?
Findings: The relative risk of developing a melanoma during the five years of follow-up was 4.33 (95% CI [4.17–4.50]) in patients who participated in the pilot targeted screening program compared with patients who did not.
Meaning: Targeted screening for melanoma allows general practitioners to focus their attention, energy, and time on at-risk populations with greater efficiency.

Le texte complet de cet article est disponible en PDF.

Abstract

Importance

Melanoma incidence and mortality rates are increasing worldwide. While screening appears to be inefficient, targeted screening might be effective.

Objective

To assess the relative risk of developing a melanoma in a population that participated in targeted screening program compared with the general population. The secondary objective was to identify the factors related to melanoma thickness at the time of diagnosis.

Design, setting, and participants

We assessed the incidence of melanoma from 2011 to 2015 in a cohort of 3832 patients at elevated risk of melanoma living on the west coast of France. The patients were older than 20 years, selected using the Self-Assessment of Melanoma risk score, and invited each spring to undergo a complete skin examination as part of a pilot targeted screening program for melanoma.

Main outcome, measures

We calculated the relative risk of developing a melanoma, based on the comparison of melanoma incidence in patients who participated in the targeted screening and in the general population in the geographic area. Data collection was performed by the regional cancer registry, in accordance with international standards. Demographical variables and histological variables related to the identification of a thick melanoma (stage 2 and higher) were also analyzed.

Results

3 169 patients developed melanomas between April 2011 and December 2015. The relative risk of developing a melanoma during the five years of follow-up was 4.33 [4.17;4.50] in patients who participated in the pilot targeted screening program compared with the general population. The following factors were associated with the identification of thick melanomas: male gender (OR = 1.40; 95% CI [1.18–1.66]), age older than 75 years (OR = 1.72; 95% CI [1.38–2.14]), and residence in a rural area (OR = 1.48; 95% CI [1.21–1.80]). The targeted screening program did not lead to a lower proportion of thick melanomas at the time of diagnosis (OR=0.48 [0.11–1.40]).

Conclusions and relevance

Targeted screening for melanoma allows general practitioners to focus their attention, energy, and time on at-risk populations with greater efficiency. However, participation in the pilot screening program was not associated with the identification of thinner melanomas at the time of diagnosis.

Trial registration

This trial was registered in the Clinical Trials database before study enrollment commenced (ClinicalTrials.gov; Registration number: NCT01610531).

Le texte complet de cet article est disponible en PDF.

Plan


© 2021  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 2

Article 100013- juin 2021 Retour au numéro
Article précédent Article précédent
  • General practitioners' experiences during the Covid-19 epidemic in the Bouches-du-Rhône department: Anxiety, impact on practice and doctor-patient relationship
  • Jenna Luzet, Any Beltran Anzola, Marc Gilibert, Barthelemy Tosello, Catherine Gire
| Article suivant Article suivant
  • Challenges in treating physician burnout: The psychologist's perspective
  • Anne-Laure Lenoir, Caroline De Troyer, Carole Demoulin, Ingrid Gillain, Marie Bayot

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.